Chlorite formulations and methods of preparation and use thereof
Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
1. A method for treating a macrophage-associated neurodegenerative disease in a patient in need thereof comprising administering to said patient a composition comprising
(i) a pharmaceutically acceptable salt of chlorite;
(ii) a pH adjusting agent; and
(iii) a pharmaceutically acceptable carrier;
wherein said composition exhibits diminished cell toxicity relative to WF10.
2. The method of claim 1 , wherein said diminished cell toxicity relative to WF10 is measured in Jurkat T cells.
3. The method of claim 1 , wherein said pharmaceutically acceptable salt of chlorite is sodium chlorite.
4. The method of claim 3 , wherein said sodium chlorite is purified to greater than about 95% purity prior to formulation in said composition.
5. The method of claim 3 , wherein said sodium chlorite is purified to greater than about 99% purity prior to formulation in said composition.
6. The method of claim 1 , wherein said composition has a pH between about 7 and about 11.5.
7. The method of claim 1 , wherein said composition has a pH between about 7 and about 9.
8. The method of claim 1 , wherein said composition contains an amount of chlorate ions and said amount of chlorate ions is in a ratio of chlorite ions to chlorate ions that is greater than 100:1.5.
9. The method of claim 1 , wherein said composition contains an amount of sulfate ions and said amount of sulfate ions is in a ratio of chlorite ions to sulfate ions that is greater than 100:16.
10. The method of claim 1 , wherein said composition is administered intravenously, orally, parenterally, subcutaneously, transdermally, or transbuccally.
11. The method of claim 10 , wherein said composition is administered intravenously.
12. The method of claim 10 , wherein said composition is administered orally.
13. The method of claim 10 , wherein said composition is administered parenterally, subcutaneously, transdermally, or transbuccally.
14. The method of claim 1 , wherein said pH adjusting agent is acetic acid.
15. The method of claim 1 , wherein said pH adjusting agent is a phosphate buffer.
16. The method of claim 1 , wherein said macrophage-associated neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Alzheimer's Disease, and multiple sclerosis.
17. The method of claim 16 , wherein said macrophage-associated neurodegenerative disease is ALS.
18. The method of claim 1 , wherein said pharmaceutically acceptable carrier is saline solution.
19. The method of claim 1 , wherein said composition is in solid form.
20. The method of claim 19 , wherein said solid form is selected from the group consisting of tablets and capsules.
21. The method of claim 1 , wherein said pharmaceutically acceptable salt of chlorite is sodium chlorite purified to greater than about 99% purity prior to formulation in said composition; wherein said composition contains an amount of chlorate ions that is less than about 1.5% chlorate ions; and wherein said composition contains an amount of sulfate ions that is less than about 0.7% sulfate ions.